DBV Technologies S.A.

ENXTPA:DBV Stock Report

Market Cap: €63.1m

DBV Technologies Valuation

Is DBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DBV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DBV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DBV?

Key metric: As DBV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DBV. This is calculated by dividing DBV's market cap by their current revenue.
What is DBV's PS Ratio?
PS Ratio5.3x
SalesUS$12.52m
Market CapUS$66.74m

Price to Sales Ratio vs Peers

How does DBV's PS Ratio compare to its peers?

The above table shows the PS ratio for DBV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.1x
ABNX ABIONYX Pharma
8.9x40.7%€43.2m
AELIS Aelis Farma
3.7x24.6%€39.5m
ALGEN genOway Société anonyme
1.2xn/a€33.3m
MAAT MaaT Pharma
42.6x59.7%€109.4m
DBV DBV Technologies
5.3x59.6%€63.1m

Price-To-Sales vs Peers: DBV is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (14.1x).

Price to Sales Ratio vs Industry

How does DBV's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
ALGEN genOway Société anonyme
1.2xn/aUS$35.26m
LYS Lysogene
0.4xn/aUS$5.42m
ALINT IntegraGen
0.3xn/aUS$3.19m
GV Genomic Vision Société Anonyme
0.4xn/aUS$746.33k
DBV 5.3xIndustry Avg. 3.5xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DBV is expensive based on its Price-To-Sales Ratio (5.3x) compared to the French Biotechs industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is DBV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DBV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ratio12.4x

Price-To-Sales vs Fair Ratio: DBV is good value based on its Price-To-Sales Ratio (5.3x) compared to the estimated Fair Price-To-Sales Ratio (12.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€115.7b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€92.31

7D

1.7%

1Y

8.8%

Vetoquinol

€925.3m

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.

VETO

€78.20

7D

-0.9%

1Y

-17.9%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

-3.1%

1Y

-56.9%